Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, Anne Schaap-Nutt, Ursula J. Buchholz, Alexander C. Schmidt, Emmalene J. Bartlett, Brian R. Murphy, Peter L. Collins

Research output: Contribution to journalArticle

Abstract

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

Original languageEnglish (US)
Pages (from-to)e143-e146
JournalJournal of the Pediatric Infectious Diseases Society
Volume4
Issue number4
DOIs
StatePublished - 2015

Keywords

  • Children
  • HPIV-1 vaccine
  • Lower respiratory tract illness

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children'. Together they form a unique fingerprint.

  • Cite this

    Karron, R. A., Mateo, J. S., Thumar, B., Schaap-Nutt, A., Buchholz, U. J., Schmidt, A. C., Bartlett, E. J., Murphy, B. R., & Collins, P. L. (2015). Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. Journal of the Pediatric Infectious Diseases Society, 4(4), e143-e146. https://doi.org/10.1093/jpids/piu104